Alexion Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Alexion Pharmaceuticals, Inc. (ALXN)

Q2 2012 Earnings Call

July 25, 2012 10:00 AM ET

Executives

Lenny Bell – CEO

Tom Dubin – SVP and Chief Legal Officer

Vikas Sinha – SVP and CFO

David Hallal – SVP, Global Commercial Operations

Steve Squinto – EVP and Head of Research and Development

Analysts

Geoff Meacham – JP Morgan

Rachel McMinn – Bank of America/Merrill Lynch

Eric Schmidt – Cowen & Company

David Friedman – Morgan Stanley

Shane – Wells Fargo

Salveen Richter – Canaccord

Geoffrey Porges – Bernstein

Navdeep Singh – Deutsche Bank

Ying Huang – Barclays

Ian Somaiya – Piper Jaffray

Matt Roden – UBS

Howard Liang – Leerink Swann

Chris Raymond – Robert Baird

Presentation

Operator

Good day, ladies and gentlemen, and welcome to the Second Quarter 2012 Alexion Pharmaceuticals Earnings Conference Call.

(Operator Instructions)

I would now like to turn the presentation over to your host for today, Dr. Bell. Please proceed, sir.

Lenny Bell

Thank you, operator, and good morning. Thank you for joining us on today’s call to discuss Alexion’s performance for the second quarter of 2012.

With me on the call this morning are members of Alexion management: Steve Squinto, Executive Vice President and Head of R&D; Vikas Sinha, Senior Vice President and Chief Financial Officer; David Hallal, Senior Vice President, Global Commercial Operations; and Tom Dubin, Senior Vice President and Chief Legal Officer. We also welcome our entire Alexion team working around the world.

Vikas, David and Steve will join me on today’s call to report on our progress in the second quarter, and to provide an update on our outlook for the second half of this year.

If you liked this article you might like

Alexion Could Target Sage, Ra Pharma: Analyst

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Stocks Come Off Highs as Apple Wait Counters Boost From Tax Reform Talk